top of page
![Pattern 5 [Converted]-01.png](https://static.wixstatic.com/media/51c62d_44f38c257d614130ace0f56455e9be12~mv2.png/v1/fill/w_980,h_718,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/51c62d_44f38c257d614130ace0f56455e9be12~mv2.png)
Knowledge Center
Search


FDA Clears HeartLung's AI-CVD®, Enabling the Broadest Opportunistic Cardiovascular & Multisystem CT Screening Platform
FDA-cleared AI-CVD® extracts preventive insights from routine CT—identifying hidden cardiovascular, metabolic, and skeletal risk in ~40M scans/year Houston, TX – January 12th, 2026 — HeartLung Corporation today announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD® , its flagship AI-powered quantitative imaging platform, under 510(k) K252029 , marking a major inflection point in preventive medicine and opportunistic screening. With this clearance, AI-CVD® be


HeartLung AI Highlights World-Renowned Scientific Advisors and New Scholarly Contribution on Heart Attack Care
Houston, TX — HeartLung AI today recognized its scientific advisors, including Robert A. Kloner, MD, PhD; Arthur Agatston, MD, FACC; Claudia Henschke, MD, PhD; and David Yankelevitz, MD, as internationally recognized pioneers whose work has helped shape modern cardiovascular prevention and lung cancer screening. As part of this leadership, HeartLung AI is highlighting a recent publication by Dr. Robert A. Kloner and colleague featured in a companion volume to Braunwald’s Hea


HeartLung Founder Dr. Morteza Naghavi Leads Authors in JACC Viewpoint Urging CMS Coverage for Coronary Calcium Imaging
Houston, TX — December 2025 — HeartLung announced today the publication of a landmark Editorial Viewpoint in JACC: Cardiovascular Imaging , led by Morteza Naghavi, MD , founder of HeartLung, urging the Centers for Medicare & Medicaid Services (CMS) to recognize coronary artery calcium (CAC) imaging as a diagnostic test and initiate national coverage. The Viewpoint, “Coronary Artery Calcium (CAC) Imaging as a Diagnostic Test: Insurance Coverage Implications,” represents the


HeartLung.AI Introduces Agatston 2.0: The next generation of calcium scoring hosted by SCCT
Agatston 2.0 and AI-CVD unveiled in a new SCCT-hosted webcast, showcasing the next generation of calcium scoring and cardiometabolic imaging. HOUSTON, TX, UNITED STATES, November 20, 2025 / EINPresswire.com / -- The Society of Cardiovascular Computed Tomography (SCCT) and HeartLung.AI today announced the release of a new sponsored webcast, “Agatston 2.0: The next generation of calcium scoring in the era of AI-CAC and AI-CVD.” The free webcast, sponsored by HeartLung.AI , br


HeartLung.AI Webcast
Hosted by Society of Cardiovascular Tomography (SCCT) Agatston 2.0: The next generation of calcium scoring in the era of AI-CAC and AI-CVD Full Video View Part 1 View Part 2 Webcast Summary Thirty years ago, the Agatston Score pioneered CT-based coronary atherosclerosis imaging. Since then, extensive evidence has established CAC as the strongest predictor of CHD events. However, two limitations have constrained its clinical utility: “Power of Zero” exceptions: Alth


HeartLung Technologies Sets New Milestone with Nine Accepted Abstracts at AHA 2025 Showcasing the Power of AI-CVD™
New Orleans, LA — October 21, 2025 — HeartLung Technologies today announced a record-setting presence at the upcoming American Heart Association (AHA) Scientific Sessions 2025, with nine peer-reviewed studies accepted for presentation—spotlighting breakthroughs from the company’s AI-CVD™ platform, including AI-CAC™ and novel CT-derived cardiometabolic imaging biomarkers. The work spans prediction of coronary “soft plaques”, heart failure, atrial fibrillation, COPD, non-zero


American Heart Association Cites HeartLung’s AI-CAC™ and AI-CVD™ Technologies in Landmark Scientific Statement on Opportunistic Screening
HOUSTON, TX — The American Heart Association (AHA) has released an official Scientific Statement in Circulation recognizing AI-enabled opportunistic detection of coronary artery calcium (CAC) on routine chest CT scans as an emerging cornerstone for cardiovascular disease prevention . The statement, titled “Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention,” highlights the tr


3DR Labs and HeartLung AI Integrate Opportunistic AI Tools for Bone and Cardiac Health
October 07, 2025 I Louisville, KY – 3DR Labs, the nation’s largest and most trusted provider of 3D medical image post-processing, today...


AI-CVD Investigators to Present at I-ELCAP’s 48th International Conference on Screening for Lung Cancer, October 9–11 in New York City
FOR IMMEDIATE RELEASE New York, NY — October 1, 2025 AI-CVD investigators will join global experts at the International Early Lung Cancer...


HeartLung.AI to Present Seven Pioneering AI-CVD™ and AI-CAC ™ Studies at European Society of Cardiology 2025 in Madrid
HeartLung AI will showcase seven abstracts at ESC 2025 on AI-CVD™, including novel AI-CAC™ for earlier, more sensitive heart disease...


HeartLung.AI Showcases Breakthrough AI-CVD™ and AI-CAC™ Technologies at SCCT 2025 in Montreal
HOUSTON, TX, UNITED STATES, July 8, 2025 / EINPresswire.com / -- HeartLung.AI , a leader in AI-powered medical imaging solutions for...


Capitol Imaging Services Partners with HeartLung Technologies to offer Artificial Intelligence-Enabled Opportunistic Screening for Osteoporosis and Heart Disease
HeartLung Technologies partners with Capitol Imaging Services to offer Artificial Intelligence-Enabled Osteoporosis Screening (AutoBMD™ AI and AutoChamber™ AI) as an add-on to CT Scans in Alabama.


Celebrating the Multifaceted Talents of HeartLung's Distinguished Advisor, World-renowned Cardiologist, Dr. Robert A. Kloner: New Album Release "Fillmore Station"
Dr. Robert A. Kloner's latest musical endeavor, "Fillmore Station," is a blend of piano-based neo-classical and new age music.


HeartLung Technologies Secures CMS Reimbursement for AutoChamber™ with New HCPCS Code
CMS has approved a new HCPCS code for AutoChamber™ AI reporting cardiac chambers volume and left ventricular mass in existing CT scans.


HeartLung Technologies welcomes medical imaging and bioengineering expert Dr. Zahi A. Fayad, PHD, to the Advisory Board
HeartLung Technologies welcomes medical imaging and bioengineering expert Dr. Zahi A. Fayad, PHD, to the Advisory Board.


HeartLung Technologies Presented 3 Groundbreaking AI Studies at BMEII 2025 New York Academy of Medicine
HeartLung showcases AI innovations at BMEII 2025, advancing healthcare with three scientific presentations.


HeartLung Technologies to launch AutoChamber™ AI at ACC 2025 and begin offering the AI services to healthcare providers
HeartLung Technologies to launch AutoChamber™ AI at ACC 2025 and begin offering the AI services to healthcare providers


HeartLung Technologies Selected as a Finalist for ACC 2025 Innovation Pitch Challenge
HeartLung Technologies Selected as a Finalist for ACC 2025 Innovation Pitch Challenge


SimonMed Imaging Partners with HeartLung.AI to Offer Artificial Intelligence-Based Osteoporosis Screening (AutoBMD™ AI) as an add-on to CT Scans Nationwide
SimonMed Imaging partners with HeartLung.AI to roll out AutoBMD™ AI for osteoporosis screening, enhancing preventive healthcare.


Expert Panel Discusses AI-Driven Innovations in Cardiovascular Imaging: Key Takeaways from RSNA 2024
Experts at RSNA 2024 discuss AI's transformative impact on cardiovascular imaging, featuring insights from HeartLung.AI., Nurea, AI4MedImagi
bottom of page
